Greenwich Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.38M Sell
140,297
-1,242
-0.9% -$32.5K 0.12% 90
2026
Q1
$3.97M Buy
141,539
+465
+0.3% +$12.4K 0.16% 74
2025
Q4
$3.51M Buy
141,074
+4,228
+3% +$107K 0.16% 78
2025
Q3
$3.49M Sell
136,846
-1,143
-0.8% -$28.2K 0.17% 73
2025
Q2
$3.35M Buy
137,989
+3,835
+3% +$89.4K 0.16% 63
2025
Q1
$3.4M Buy
134,154
+3,673
+3% +$96.1K 0.26% 50
2024
Q4
$3.46M Sell
130,481
-5,982
-4% -$162K 0.24% 51
2024
Q3
$3.95M Buy
136,463
+3,616
+3% +$105K 0.27% 46
2024
Q2
$3.72M Sell
132,847
-642
-0.5% -$17.7K 0.27% 46
2024
Q1
$3.7M Buy
133,489
+10,709
+9% +$297K 0.3% 47
2023
Q4
$3.54M Sell
122,780
-352
-0.3% -$10.6K 0.35% 44
2023
Q3
$4.08M Sell
123,132
-1,010
-0.8% -$35.7K 0.43% 35
2023
Q2
$4.55M Buy
124,142
+438
+0.4% +$17K 0.48% 30
2023
Q1
$5.05M Buy
123,704
+461
+0.4% +$19.9K 0.55% 24
2022
Q4
$6.32M Buy
123,243
+135
+0.1% +$6.47K 0.69% 21
2022
Q3
$5.39M Sell
123,108
-355
-0.3% -$17.3K 0.57% 21
2022
Q2
$6.47M Buy
123,463
+476
+0.4% +$24.3K 0.86% 19
2022
Q1
$6.37M Sell
122,987
-219
-0.2% -$11.4K 0.65% 22
2021
Q4
$7.28M Buy
123,206
+2,648
+2% +$131K 0.59% 21
2021
Q3
$5.18M Buy
120,558
+9,159
+8% +$406K 0.43% 24
2021
Q2
$4.36M Buy
111,399
+3,994
+4% +$155K 0.37% 31
2021
Q1
$3.89M Sell
107,405
-1,004
-0.9% -$35.6K 0.31% 34
2020
Q4
$3.99M Sell
108,409
-6,716
-6% -$246K 0.35% 31
2020
Q3
$4.01M Buy
115,125
+24
+0% +$841 0.72% 25
2020
Q2
$3.57M Buy
115,101
+612
+0.5% +$20.8K 0.68% 27
2020
Q1
$3.54M Buy
114,489
+3,916
+4% +$133K 0.76% 29
2019
Q4
$4.11M Buy
110,573
+503
+0.5% +$17.9K 0.83% 28
2019
Q3
$3.75M Sell
110,070
-1,500
-1% -$54.5K 0.73% 30
2019
Q2
$4.59M Sell
111,570
-3,387
-3% -$134K 0.79% 25
2019
Q1
$4.63M Sell
114,957
-701
-0.6% -$28.1K 0.82% 25
2018
Q4
$4.79M Buy
115,658
+599
+0.5% +$24.9K 0.95% 23
2018
Q3
$4.81M Buy
115,059
+811
+0.7% +$31.2K 0.84% 24
2018
Q2
$3.93M Buy
114,248
+3,083
+3% +$105K 0.7% 30
2018
Q1
$3.74M Buy
111,165
+418
+0.4% +$14.4K 0.59% 34
2017
Q4
$3.81M Buy
110,747
+3,336
+3% +$114K 0.64% 32
2017
Q3
$3.64M Sell
107,411
-14,681
-12% -$472K 0.63% 31
2017
Q2
$3.89M Sell
122,092
-510
-0.4% -$16.1K 0.65% 30
2017
Q1
$3.98M Sell
122,602
-20,786
-14% -$655K 0.53% 30
2016
Q4
$4.42M Buy
143,388
+1,254
+0.9% +$38.3K 0.56% 26
2016
Q3
$4.57M Sell
142,134
-65
-0% -$2.17K 0.81% 22
2016
Q2
$4.75M Buy
142,199
+937
+0.7% +$29.9K 1.15% 18
2016
Q1
$3.97M Sell
141,262
-21,563
-13% -$616K 1.03% 17
2015
Q4
$4.99M Hold
162,825
1.22% 16
2015
Q3
$4.85M Sell
162,825
-181,303
-53% -$5.81M 1.17% 21
2015
Q2
$10.9M Sell
344,128
-79,084
-19% -$2.58M 1.4% 24
2015
Q1
$14M Sell
423,212
-25
-0% -$795 1.58% 18
2014
Q4
$12.5M Buy
423,237
+99
+0% +$2.84K 0.83% 26
2014
Q3
$11.9M Buy
423,138
+50
+0% +$1.4K 0.8% 27
2014
Q2
$11.9M Sell
423,088
-69
-0% -$1.97K 0.79% 28
2014
Q1
$12.9M Sell
423,157
-47
-0% -$1.4K 0.9% 24
2013
Q4
$12.3M Sell
423,204
-359
-0.1% -$10.4K 1.24% 29
2013
Q3
$11.5M Buy
423,563
+252
+0.1% +$6.86K 0.83% 26
2013
Q2
$11.2M Buy
+423,311
New +$11.7M 0.83% 29

Other funds holding PFE

Greenwich Wealth Management's PFE Position: Q2 2026 in Review

Greenwich Wealth Management reduced its Pfizer (PFE) stake by 0.88% in Q2 2026, selling an estimated $32.5K and leaving 140,297 shares worth $3.38M. The position accounts for 0.12% of the portfolio, ranked #90.

Greenwich Wealth Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $14M in Q1 2015. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Greenwich Wealth Management held 140,297 shares of Pfizer worth $3.38M as of Q2 2026.
  • Greenwich Wealth Management sold 1,242 Pfizer shares in Q2 2026, an estimated $32.5K.
  • Pfizer made up 0.12% of Greenwich Wealth Management's portfolio in Q2 2026, its #90 holding.
  • Greenwich Wealth Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Greenwich Wealth Management's Pfizer position peaked at $14M in Q1 2015.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Greenwich Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.